Le Lézard
Classified in: Health
Subject: PER

Availity Selects Veteran Healthcare Leader Jim McNary as Chief Operating Officer


JACKSONVILLE, Fla., Oct. 19, 2021 /PRNewswire/ -- Availity, one the nation's largest real-time health information networks, announced today that Jim McNary has joined the company as chief operating officer (COO). As COO, McNary is responsible for leading cross-departmental operations, refining business processes, and maintaining alignment throughout the company for both organic and inorganic initiatives. Availity's technology, product management, implementations, and strategy/corporate development teams will report to McNary.

To download a photo of Jim McNary, please click here.

As the central platform that connects health plans and health care providers nationwide, Availity needed a COO who understood the unique complexities of the healthcare industry and the processes necessary to drive meaningful improvement; Jim McNary's distinguished career make him an ideal fit for the healthcare platform company. In his most recent role, McNary served as chief executive officer of Consortium Health Plans where he was charged with helping to position Blue Cross Blue Shield as the preferred carrier for national accounts. Prior to this, McNary served as the North American Business Leader for Mercer Health & Benefits. McNary joined Mercer from the Boston Consulting Group (BCG) where he was a member of the healthcare practice area. Prior to working at BCG, he served as an officer in the U.S. Navy SEAL teams. 

McNary conducted his undergraduate studies at Vanderbilt University. He completed his graduate work at Harvard University, earning an MBA from the Harvard Business School as well as a master's degree in public administration from Harvard's John F. Kennedy School of Government.

"It is my great pleasure to welcome Jim to Availity's executive leadership team," said Russ Thomas, chief executive officer, Availity. "Not only is Jim the kind of person who excels wherever he goes, but he does so while living a life of service to others. It's this combination of IQ and EQ that makes Jim the right person both for our leadership team and our culture as we enter an exciting, high growth chapter at Availity."  

About Availity
Availity is the place where healthcare finds the answers needed to shift focus back to patient care. We work to solve communication challenges in healthcare by creating a richer, more transparent exchange of information among health plans, providers, and technology partners. As one of the nation's largest health information networks, Availity facilitates billions of clinical, administrative, and financial transactions annually. Our suite of dynamic products, built on a powerful, intelligent platform, enables real-time collaboration for success in a competitive, value-based care environment. 

For more information, including an online demonstration, please visit www.availity.com or call 1.800.AVAILITY (282.4548).

Media Contact:
Maddie Noteboom
Amendola Communications for Availity
512.422.3425
maddie@acmarketingpr.com

 

SOURCE Availity


These press releases may also interest you

at 06:35
ImmunoGen Inc. , a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced positive top-line data from the pivotal SORAYA trial evaluating the safety and efficacy of mirvetuximab soravtansine...

at 06:35
NovaQuest Capital Management, LLC ("NovaQuest"), a biopharma and life sciences investment firm specializing in human and animal health investing, and TechAccel LLC ("TechAccel"), a technology and venture development organization, announced today that...

at 06:35
AstraZeneca and Merck , known as MSD outside the United States and Canada, today announced that a supplemental New Drug Application (sNDA) for LYNPARZA has been accepted and granted priority review by the U.S. Food and Drug Administration (FDA) for...

at 06:35
AstraZeneca's supplemental New Drug Application (sNDA) for LYNPARZAŽ (olaparib) has been accepted and granted Priority Review in the US for the adjuvant treatment of patients with BRCA-mutated (BRCAm) HER2-negative high-risk early breast cancer who...

at 06:30
Atmofizer Technologies Inc.  (the "Company" or "Atmofizer") is pleased to announce that Kemper GmbH, a  leading welding fume extraction equipment manufacturer and important supplier of ambient air cleaning systems, is partnering with Atmofizer to...

at 06:30
The "Nanobiotechnologies - Applications, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering. The report starts with an introduction to various techniques and materials that are relevant to...



News published on 19 october 2021 at 08:20 and distributed by: